424 related articles for article (PubMed ID: 33643443)
21. Integrative genomic analysis of drug resistance in
Xu Y; Gu L; Li Y; Zhao R; Jian H; Xie W; Liu L; Wu H; Ren F; Han Y; Lu S
Front Oncol; 2022; 12():1024818. PubMed ID: 36338758
[TBL] [Abstract][Full Text] [Related]
22. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
Jamme P; Fernandes M; Copin MC; Descarpentries C; Escande F; Morabito A; Grégoire V; Jamme M; Baldacci S; Tulasne D; Kherrouche Z; Cortot AB
J Thorac Oncol; 2020 May; 15(5):741-751. PubMed ID: 32169477
[TBL] [Abstract][Full Text] [Related]
23. Going After
Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
[TBL] [Abstract][Full Text] [Related]
24. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring
Le X; Hong L; Hensel C; Chen R; Kemp H; Coleman N; Ciunci CA; Liu SV; Negrao MV; Yen J; Xia X; Scheuenpflug J; Stroh C; Juraeva D; Tsao A; Hong D; Raymond V; Paik P; Zhang J; Heymach JV
JCO Precis Oncol; 2021; 5():. PubMed ID: 34957368
[TBL] [Abstract][Full Text] [Related]
25. Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics.
Guo MZ; Marrone KA; Spira A; Waterhouse DM; Scott SC
Onco Targets Ther; 2021; 14():5321-5331. PubMed ID: 34853516
[No Abstract] [Full Text] [Related]
26. Narrative review: mesenchymal-epithelial transition inhibitors-meeting their target.
Safi D; Abu Hejleh T; Furqan M
Transl Lung Cancer Res; 2021 Jan; 10(1):462-474. PubMed ID: 33569327
[TBL] [Abstract][Full Text] [Related]
27. An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.
Teishikata T; Shiraishi K; Shinno Y; Kobayashi Y; Kashima J; Ishiyama T; Yoshida T; Mori T; Yatabe Y
J Thorac Oncol; 2021 Dec; 16(12):2133-2138. PubMed ID: 34419686
[TBL] [Abstract][Full Text] [Related]
28. Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report.
Chen Z; Zhu F; Li C; Li J; Cheng B; Xiong S; Zhong R; Liang W; He J
Ann Transl Med; 2021 Mar; 9(5):424. PubMed ID: 33842645
[TBL] [Abstract][Full Text] [Related]
29. MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G; Trillo Aliaga P; Attili I; Del Signore E; Corvaja C; Corti C; Uliano J; Passaro A; de Marinis F
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835473
[TBL] [Abstract][Full Text] [Related]
30. Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.
Sui JSY; Finn SP; Gray SG
Methods Mol Biol; 2021; 2279():145-155. PubMed ID: 33683691
[TBL] [Abstract][Full Text] [Related]
31. Capmatinib for the treatment of non-small cell lung cancer.
Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
[No Abstract] [Full Text] [Related]
32. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
Hsu R; Benjamin DJ; Nagasaka M
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509224
[TBL] [Abstract][Full Text] [Related]
33. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
Tseng LW; Chang JW; Wu CE
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
[TBL] [Abstract][Full Text] [Related]
34. Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples.
O'Brien O; Wright MC; O'Brien C; Geoghegan O; Leonard N; Nicholson S; Cuffe S; Fabre A; Jochum W; Joerger M; Gray SG; Finn SP
Diagnostics (Basel); 2019 Jan; 9(1):. PubMed ID: 30669306
[TBL] [Abstract][Full Text] [Related]
35. Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report.
Onodera Y; Sekine A; Hagiwara E; Yamada S; Ikeda S; Tabata E; Kitamura H; Baba T; Komatsu S; Okudela K; Ogura T
Mol Clin Oncol; 2023 Jun; 18(6):49. PubMed ID: 37228358
[TBL] [Abstract][Full Text] [Related]
36. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With
Lau SCM; Perdrizet K; Fung AS; Mata DGMM; Weiss J; Holzapfel N; Liu G; Bradbury PA; Shepherd FA; Sacher AG; Feilotter H; Sheffield B; Hwang D; Tsao MS; Cheng S; Cheema P; Leighl NB
JTO Clin Res Rep; 2023 Oct; 4(10):100562. PubMed ID: 37744308
[TBL] [Abstract][Full Text] [Related]
37. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
38. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
Yin L; Lu Y
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):553-559. PubMed ID: 30037377
[TBL] [Abstract][Full Text] [Related]
39. Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Xiong W; Hietala SF; Nyberg J; Papasouliotis O; Johne A; Berghoff K; Goteti K; Dong J; Girard P; Venkatakrishnan K; Strotmann R
Cancer Chemother Pharmacol; 2022 Jul; 90(1):53-69. PubMed ID: 35771259
[TBL] [Abstract][Full Text] [Related]
40. Tepotinib hydrochloride for the treatment of non-small cell lung cancer.
Wu ZX; Li J; Dong S; Lin L; Zou C; Chen ZS
Drugs Today (Barc); 2021 Apr; 57(4):265-275. PubMed ID: 33851690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
